Interesting product but I don't see the ned benefit to VIV in a merger of the two.  Kane's product probably doesn't have a whole lot of IP behind it, and their distribution is probably no better than that for VIV - nascent.  Avivagen is taking its time getting other distribution agreements signed which is frustrating, but I understand that it's an ongoing process...  they have a lot to deliver on in the near-term and I'm hopeful they do.  They're probably better off on their own - a merger is a huge distraction.

Hank's press release was a nice recap of last year, but pretty thin on detail in terms of what's to come.  It would be nice if they'd take the risk and put something meaningful in print and then stick to it.  No more soft press releases.  Attendance numbers at Woofstock is hardly going to get this story/stock moving...